PA
OTLK icon

Perceptive Advisors’s Outlook Therapeutics OTLK Stock Holding History

Perceptive Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,237
Closed -$837K – 149
2017
Q2 		$837K Sell
5,237
-2,150
-29% -$607K 0.04% 98
2017
Q1 		$3.17M Sell
7,387
-419
-5% -$208K 0.18% 72
2016
Q4 		$3.76M Hold
7,806
– – 0.27% 68
2016
Q3 		$5.31M Sell
7,806
-399
-5% -$254K 0.34% 67
2016
Q2 		$4.46M Buy
+8,205
New +$4.89M 0.31% 62

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Perceptive Advisors's OTLK Position: Q3 2017 in Review

Perceptive Advisors sold out of Outlook Therapeutics (OTLK) in Q3 2017, closing a stake of 5,237 shares — an estimated $837K sold.

Perceptive Advisors first reported a position in OTLK in Q2 2016 and held it in 5 quarters. The position peaked at $5.31M in Q3 2016. 17 funds tracked by Wall St. Rank hold OTLK as of Q3 2017.

  • Perceptive Advisors reported no remaining Outlook Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Perceptive Advisors sold 5,237 Outlook Therapeutics shares in Q3 2017, an estimated $837K.
  • Perceptive Advisors first reported a position in Outlook Therapeutics in Q2 2016 and held it in 5 quarters.
  • Perceptive Advisors's Outlook Therapeutics position peaked at $5.31M in Q3 2016.
  • 17 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2017.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.